Research Paper Volume 13, Issue 6 pp 8975—8988

PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival

PFS of breast or ovarian cancer patients with BRCAm treated with PARPis.

Figure 2. PFS of breast or ovarian cancer patients with BRCAm treated with PARPis.